These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26209838)

  • 1. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
    Shimabukuro TT; Nguyen M; Martin D; DeStefano F
    Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
    Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
    Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
    Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Announcement: Implementation of the Vaccine Adverse Event Reporting System 2.0 Reporting Form.
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):738. PubMed ID: 28704349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group.
    Singleton JA; Lloyd JC; Mootrey GT; Salive ME; Chen RT
    Vaccine; 1999 Jul; 17(22):2908-17. PubMed ID: 10438063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
    Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form.
    Suragh TA; Miller ER; Hibbs BF; Winiecki SK; Zinderman C; Shimabukuro TT
    Vaccine; 2017 Apr; 35(18):2295-2297. PubMed ID: 28351735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
    Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
    Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
    Myers TR; McNeil MM; Ng CS; Li R; Marquez PL; Moro PL; Omer SB; Cano MV
    Vaccine; 2020 Sep; 38(40):6291-6298. PubMed ID: 32747215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.